Sign In
Buy BNTX
$90.58
-2.27 (-2.44%)
At Close: Jul 31, 2026
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
05:44am, Wednesday, 18'th Dec 2024
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
US FDA lifts partial clinical hold on BioNTech cancer drug study
04:12pm, Friday, 13'th Dec 2024
BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a ty
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
05:50am, Wednesday, 11'th Dec 2024
I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other
2 No-Brainer Stocks to Buy Before the End of 2024
05:50am, Monday, 09'th Dec 2024
I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares this opinion.
Why Is BioNTech Stock Trading Higher On Friday?
01:14pm, Friday, 06'th Dec 2024
On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE BNTX.
5 Top Stocks to Buy in December
05:45am, Wednesday, 04'th Dec 2024
The end of the year can spur myriad feelings when deciding which stocks are the best buys.
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.
11:57am, Tuesday, 19'th Nov 2024
Evercore ISI analyst Cory Kasimov upgrades the German drugmaker's stock to Outperform from In Line.
Analysts Turn Bullish on BioNTech Stock Amid Volatility
10:19am, Tuesday, 19'th Nov 2024
BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line.
BioNTech and Moderna at vanguard of new treatment wave - but which is best?
05:14am, Tuesday, 19'th Nov 2024
The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the po
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
12:55pm, Friday, 15'th Nov 2024
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme
European And US Vaccine Stocks Are Under Pressure - Here's WHy
11:21am, Friday, 15'th Nov 2024
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
11:45am, Thursday, 14'th Nov 2024
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
BioNTech buys China's Biotheus to support oncology strategy
06:52am, Wednesday, 13'th Nov 2024
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on We
BioNTech to Acquire Biotheus to Boost Oncology Strategy
06:45am, Wednesday, 13'th Nov 2024
MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquis
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
02:12pm, Saturday, 09'th Nov 2024
Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.
